Gamma secretase-activating protein is a substrate for caspase-3: Implications for Alzheimer's disease

Biological Psychiatry

Volumn 77, Issue 8, 2015, Pages 720-728

  Chu, Jin ^a   Li, Jian Guo ^a   Joshi, Yash B ^a   Giannopoulos, Phillip F ^a   Hoffman, Nicholas E ^a   Madesh, Muniswamy ^a   Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Caspase 3; Gamma secretase; Gamma secretase activating protein; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 3; GAMMA SECRETASE; GAMMA SECRETASE ACTIVATING PROTEIN; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVATING PROTEIN, HUMAN; PRESENILIN 1; PROTEIN; PSEN1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

AGED; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID PLAQUE; ANIMAL MODEL; ARTICLE; BIOGENESIS; BRAIN; BRAIN TISSUE; CADAVER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR BIOLOGY; MOUSE; NERVE CELL; NEUROBIOLOGY; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; VERY ELDERLY; ANIMAL; FRONTAL LOBE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; MUTAGENESIS; MUTATION; NEUROBLASTOMA; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CASPASE 3; CELL LINE, TUMOR; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPRECIPITATION; MALE; MICE; MICE, TRANSGENIC; MUTAGENESIS; MUTATION; NEUROBLASTOMA; PRESENILIN-1; PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84933279721     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.06.003     Document Type: Article

References (23)

1. Gandy S (2012): Lifelong management of amyloid beta metabolism to prevent Alzheimer's disease. N Engl J Med 367:864-866.
2. He G, Luo W, Remmers C, Netzer WJ, Hendrick J, Bettayeb K, et al. (2010): Gamma-secretase activating protein, a therapeutic target for Alzheimer's disease. Nature 467:95-98.
3. Deatherage CL, Hadziselimovic A, Sanders CR (2012): Purification and characterization of human gamma-secretase activating protein. Biochemistry 51:5153-5159.
4. Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, Katayama T, et al. (2006): TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440:1208-1212.
5. Chu J, Praticò D (2011): 5-Lipoxygenase as an endogenous modulator of amyloid-beta formation in vivo. Ann Neurol 69:34-46.
6. Chu J, Li JG, Ceballos-Diaz C, Golde T, Praticò D (2013): The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: In vivo and in vitro evidence. Biol Psychiatry 74:321-328.
7. Kobayashi T, Mikami S, Yokoyama S, Imataka H (2007): An improved cell-free system for picornavirus synthesis. J Virol Methods 142: 182-188.
8. Shineman D, Zhang B, Leight SN, Pratico D, Lee VM (2008): Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice. J Neurosci 28:4785-4794.
9. Firuzi O, Zhuo J, Chinnici C, Wisnieski T, Praticò D (2008): 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J 22:1169-1178.
10. Zhou S, Zhou H, Walian PJ, Jap BK (2007): Regulation of gamma-secretase activity in Alzheimer's disease. Biochemistry 46:2553-2563.
11. Kishi T, Hirooka Y, Konno S, Ogawa K, Sunagawa K (2010): Angiotensin II type 1 receptor-activated caspase-3 through ras/mitogen-activated protein kinase/extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympatho-excitation in stroke-prone spontaneously hypertensive rats. Hypertension 55: 291-297.
12. Stepanichev MY, Kudryashova IV, Yakovlev AA, Onufriev MV, Khaspekov LG, Lyzhin AA, et al. (2005): Central administration of a caspase inhibitor impairs shuttle-box performance in rats. Neuro- Science 136:579-591.
13. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, et al. (1996): Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
14. Oddo A, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. (2003): Triple transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39:409-421.
15. Satoh J, Tabunoki H, Ishida T, Saito Y, Arima K (2012): Immunohistochemical characterization of γ-secretase-activating protein expression in Alzheimer's disease brain. Neuropathol App Neurobiol 38: 132-141.
16. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hillbush BS (2011): Peripheral reduction of b-amyloid is sufficient to reduce brain beta-amyloid. Implications for Alzheimer's disease. J Neurosci Res 89:808-814.
17. Hussain I, Fabregue J, Anderes L, Ousson S, Borlat F, Eligert V, et al. (2013): The role of gamma-secretase-activating protein (GSAP) and imatinib in the regulation of gamma-secretase activity and amyloid-beta generation. J Biol Chem 288:2521-2531.
18. Chu J, Lauretti E, Craige C, Praticò D (2014): Pharmacological modulation of GSAP reduces amyloid b levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles [published online ahead of print March 24]. J Alzheimer's Dis.
19. Marin N, Romero B, Bosch-Morell F, Lansola M, Felipo V, Romá J, et al. (2000): Beta-amyloid-induced activation of caspase-3 in primary cultures of rat neurons. Mech Ageing Dev 119:63-67.
20. Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Brück W, Jellinger K, et al. (1999): Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol 155: 1459-1466.
21. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. (1999): Involvement of caspases in proteolytic cleavage of Alzheimer's disease amyloid-beta precursor protein and amyloidogenic Abeta peptide formation. Cell 97:395-406.
22. Louneva N, Cohen JW, Han LY, Talbot K, Wilson RS, Bennett DA, et al. (2008): Caspase-3 is enriched in post-synaptic densities and increased in Alzheimer's disease. Am J Pathol 173: 1488-1495.
23. D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, et al. (2011): Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 14:69-76.